CARE maintains fundamental grade of 3/5 on Elder Pharma

CARE Equity Research has come out with its report on Elder Pharmaceuticals Limited (EPL). The research firm has maintained the fundamental grade of 3/5 on the company, which indicates ‘Good Fundamentals’.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
Real-time Stock quotes, portfolio, LIVE TV and more.
GeStepAhead Travelcafe SME Special
moneycontrol.com

Home » News » CARE Research

Apr 02, 2012, 12.17 PM | Source: Moneycontrol.com

CARE maintains fundamental grade of 3/5 on Elder Pharma

CARE Equity Research has come out with its report on Elder Pharmaceuticals Limited (EPL). The research firm has maintained the fundamental grade of 3/5 on the company, which indicates ‘Good Fundamentals’.

Like this story, share it with millions of investors on M3

CARE maintains fundamental grade of 3/5 on Elder Pharma

CARE Equity Research has come out with its report on Elder Pharmaceuticals Limited (EPL). The research firm has maintained the fundamental grade of 3/5 on the company, which indicates ‘Good Fundamentals’.

Post Your Comments

Share Cancel

(more)

, CARE Equity Research |

CARE Equity Research has come out with its report on Elder Pharmaceuticals Limited (EPL). The research firm has maintained the fundamental grade of 3/5 on the company, which indicates ‘Good Fundamentals’.

Healthy growth in revenue: EPL posted consolidated revenue of Rs.343 crore in Q3FY12 (refers to period October, 1 – December, 31) – a y-o-y growth of 36.4 per cent. On a standalone basis the company reported revenue of Rs.256.8 crore - up 23 per cent, y-o-y. All therapeutic segments witnessed healthy growth in the quarter.

New product launches: EPL continued its strategy to enhance its product portfolio through new launches in Q3FY12. The company launched six new products, four in anti-infectives and one each in women healthcare and pain management segment in Q3FY12. The company is further planning to add more new products to its portfolio in Q4FY12. New product launches would be a critical monitorable for sustaining the growth in EPL’s top-line going forward.

Margins witness some pressure: EPL’s margins witnessed some pressure in Q3FY12 when compared with Q3FY11. The same was primarily on account of higher materials cost due to increase in input prices and depreciation in Rupee against USD. Consequently, net margins too witnessed a decline y-o-y and stood at 5.3 per cent in Q3FY12. However, on a standalone basis the margins have witnessed improvement.

Valuation: CARE Equity Research maintains the CIV of Rs.434 for the shares of EPL. At the Current Market Price (CMP) of Rs.339 per share, CARE assigns a valuation grade of 5/5, indicating that shares of EPL have ‘Considerable Upside Potential’ at the CMP.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
CARE maintains fundamental grade of 3/5 on Elder Pharma

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login